<DOC>
	<DOCNO>NCT01023893</DOCNO>
	<brief_summary>Prospective , real-time observational study hemodialysis patient treat erythropoiesis-stimulating agent ( ESA ) currently recommend Hgb target . Subjects evaluate dynamically blood viscosity status begin end dialysis treatment , follow prospectively assess outcome . Blood specimen collect via subject 's hemodialysis port pre- post-hemodialysis per study assessment visit . Blood analyze designated laboratory facility viscosity comprehensive range shear rate test intradialytic surge blood viscosity . Subjects follow 48 week .</brief_summary>
	<brief_title>Blood Viscosity , End-Stage Renal Disease , And Mortality ( BEAM-1 )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Age &gt; 18 year old On hemodialysis &gt; 3 month On ESA treatment &gt; 3 month Mean Hgb 11 g/dL 12 g/dL ( base least 3 Hgb result previous 8 week ) Latest Hgb 10.5 g/dL 12.5 g/dL ( measure within 1 week study ) Inability unwillingness provide inform consent Large variability interdialytic weight gain ( &gt; 2 kg difference low high weight gain last month ) More 1 missed dialysis treatment past month Recent bleed Blood transfusion within 1 month Hematologic disease anemia Active inflammatory disease Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>